van der Wall E E, Niemeyer M G, de Roos A, Bruschke A V, Pauwels E K
Department of Cardiology, University Hospital Leiden, The Netherlands.
Eur J Nucl Med. 1990;17(1-2):83-90. doi: 10.1007/BF00819409.
Assessment of myocardial infarct size is the cornerstone in the evaluation of interventions designed to salvage myocardium, such as thrombolytic therapy and urgent coronary angioplasty. Enzymatic methods have probably the highest accuracy but can only be used in the very early phase of infarction. The electrocardiogram allows a reasonable estimate of infarct size, but its confidence limits are wide, and in inferior wall infarction the estimates are unreliable. In recent years, radionuclide techniques have been successfully used to identify, localize and determine infarct size in the course of acute myocardial infarction. These scintigraphic measurements have provided important diagnostic, therapeutic and prognostic information based on the extent of myocardial damage. Nuclear magnetic resonance imaging, particularly with contrast enhancement, is one of the methods that have the greatest potential in accurately delineating myocardial infarct size. Nuclear medicine procedures, on the other hand, employ more biologically oriented tracers and offer promise in view of their ability to monitor biochemical alterations as an effect of therapy in the course of myocardial infarction.
评估心肌梗死面积是评估旨在挽救心肌的干预措施(如溶栓治疗和紧急冠状动脉血管成形术)的基石。酶学方法可能具有最高的准确性,但仅能在梗死的极早期使用。心电图可以对梗死面积进行合理估计,但其置信区间较宽,在下壁梗死中,估计结果并不可靠。近年来,放射性核素技术已成功用于识别、定位和确定急性心肌梗死过程中的梗死面积。这些闪烁扫描测量基于心肌损伤程度提供了重要的诊断、治疗和预后信息。核磁共振成像,尤其是对比增强成像,是在准确描绘心肌梗死面积方面最具潜力的方法之一。另一方面,核医学程序使用更具生物学导向的示踪剂,鉴于其能够监测作为心肌梗死治疗效果的生化改变,因而具有前景。